摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3',4'-dihydrospiro[cyclohexane-1,2'-(1'H)-naphthalen]-1'-one | 7416-01-5

中文名称
——
中文别名
——
英文名称
3',4'-dihydrospiro[cyclohexane-1,2'-(1'H)-naphthalen]-1'-one
英文别名
3',4'-dihydro-spiro[cyclohexane-1,2'-naphthalen]-1'-one;3',4'-Dihydro-spiro[cyclohexan-1,2'-naphthalin]-1'-on;1-Oxo-1,2,3,4-tetrahydro-naphthalin-2-spirocyclohexan;1,2-Benzo-cyclohexenon-3-4-spiro-1'-cyclohexan;2,2-Pentamethylen-tetralon-(1);Spiro[3,4-dihydronaphthalene-2,1'-cyclohexane]-1-one
3',4'-dihydrospiro[cyclohexane-1,2'-(1'H)-naphthalen]-1'-one化学式
CAS
7416-01-5
化学式
C15H18O
mdl
——
分子量
214.307
InChiKey
CAIYBPDHKCKHQY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    145 °C(Press: 3 Torr)
  • 密度:
    1.07224 g/cm3

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    16
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.53
  • 拓扑面积:
    17.1
  • 氢给体数:
    0
  • 氢受体数:
    1

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Synthetic Morphinans and Hasubanans. Part IV. Total Synthesis of 3,14-Dihydroxyisomorphinans, 3-Methoxy-Δ<sup>8,14</sup>-morphinans, and 9α-Hydroxy-3-methoxyhasubanan
    作者:Ivo Monković、Henry Wong、Bernard Belleau、Irwin J. Pachter、Yvon G. Perron
    DOI:10.1139/v75-358
    日期:1975.9.1

    The synthesis of a versatile intermediate 4a-(2-aminoethyl)-l,2,3,4,4a,9-hexahydro-6-methoxyphenanthrene (3a) and its utilization in the synthesis of 9α-hydroxy-3-methoxy-17-methylhasubanan (10), 3,14-dimethoxy-17-methylisomorphinan (9l), various 14-hydroxyisomorphinans (9), and 3-methoxy-Δ8,14-morphinan (11b) is described. A number of 17-alkyl-3,14-dihydroxyisomorphinans were prepared and tested for narcotic antagonist and analgesic activities in laboratory animals. Some of these new compounds have exhibited significant activities.

    合成了一种多用途中间体4a-(2-氨基乙基)-1,2,3,4,4a,9-六氢-6-甲氧基菲(3a),并研究了其在9α-羟基-3-甲氧基-17-甲基哈苏班烷(10)、3,14-二甲氧基-17-甲基异吗啡烷(9l)、各种14-羟基异吗啡烷(9)和3-甲氧基-Δ8,14-吗啡烷(11b)合成中的应用。制备了一系列17-烷基-3,14-二羟基异吗啡烷,并在实验动物中测试了它们的麻醉拮抗和镇痛活性。其中一些新化合物表现出显著的活性。

  • Azetidinone compound and process for preparation thereof
    申请人:TANABE SEIYAKU CO., LTD.
    公开号:EP0597423A2
    公开(公告)日:1994-05-18
    There is disclosed an azetidinone compound of the formula [I]: wherein Ring B is a benzene ring which may have substituent(s), R¹ is a hydroxy-substituted lower alkyl group which may have substituent(s), X is oxygen atom and the like, Y is oxygen atom and the like, and Z is a methylene group which may have substituent(s), which is useful as a synthetic intermediate of the 1β-methylcarbapenem-type antibacterial agent.
    本发明公开了一种式[I]的氮杂环丁酮化合物: 其中环 B 是可能具有取代基的苯环,R¹ 是可能具有取代基的羟基取代的低级烷基,X 是氧原子等,Y 是氧原子等,Z 是可能具有取代基的亚甲基,该化合物可用作 1β-甲基碳青霉烯类抗菌剂的合成中间体。
  • Synthesis and pharmacological evaluation of 4a-phenanthrenamine derivatives acting at the phencyclidine binding site of the N-methyl-D-aspartate receptor complex
    作者:Christopher F. Bigge、Thomas C. Malone、Sheryl J. Hays、Graham Johnson、Perry M. Novak、Leonard J. Lescosky、Daniel M. Retz、Daniel F. Ortwine、Albert W. Probert
    DOI:10.1021/jm00066a007
    日期:1993.7
    A novel series of octahydrophenanthrenamines and their heterocyclic analogues have been synthesized as potential noncompetitive antagonists of the N-methyl-D-aspartate (NMDA) receptor complex. The compounds were evaluated for their affinity at the phencyclidine (PCP) binding site by determining their ability to displace [H-3]TCP from crude rat brain synaptic membranes. A wide range of affinities were observed, with the most potent analogs possessing IC50's equivalent to that of the reference agent MK-801 (3,dizocilpine). NMDA antagonist activity was demonstrated by prevention of glutamate-induced accumulation of [Ca-45(2+)] in cultured rat cortical neurons. Selected compounds were also studied in vivo to determine their ability to prevent the lethal effects of systemically injected NMDA in the mouse. In general, the SAR of the phenanthrenamine series may be summarized as follows: (a) for the amino group at C4a, NHMe > NH2 > NHEt much-greater-than NC5H10; (b) for the B-ring substitution, X = CH2 > S > 0; (c) unsaturation of the C ring decreases receptor affinity; (d) cis-ring fusion between the B and C rings is desirable; (e) 6-hydroxy or 6-methoxy substitution of the phenanthrenamine system identified an additional hydrogen bonding interaction that substantially increased receptor affinity; (f) spiro analogues (such as 55, IC50 = 3400 nM), which altered the point of attachment of the C ring, caused a substantial reduction in PCP-site affinity. Molecules from this series were useful for refining a pharmacophore model consistent with previous models of the PCP site. In this model, the (R)-(+)-phenanthrenamine 13 superimposes closely onto MK-801 (3), and the angular 4a-amino group is believed to hydrogen bond with a putative receptor site atom. In the phenanthrenamine and thiaphenanthrenamine series, the (R)-(+)-enantiomers (9, 13, and 44) are more potent by approximately 5-10-fold than their corresponding (S)-(-)-enantiomers with respect to their affinity for the PCP site, their ability to prevent accumulation of [Ca-45(2+)] in cultured neuronal cells, and their protection against the lethal effects of NMDA in mice. In general, there was no separation between the dose that prevented NMDA lethality and the dose that produced ataxia in mice, except in the case of the thiaphenanthrenamines 41 and 43. We have not yet obtained evidence that this small separation in activity offers a therapeutic advantage in the treatment of cerebral ischemia or other neurodegenerative disorders.
  • Mousseron et al., Bulletin de la Societe Chimique de France, 1957, p. 346,352
    作者:Mousseron et al.
    DOI:——
    日期:——
  • Sen-Gupta, Journal of the Indian Chemical Society, 1942, vol. 19, p. 467,471
    作者:Sen-Gupta
    DOI:——
    日期:——
查看更多

同类化合物

(S)-(+)-5,5'',6,6'',7,7'',8,8''-八氢-3,3''-二叔丁基-1,1''-二-2-萘酚,双钾盐 顺式-4-(4-氯苯基)-1,2,3,4-四氢-N-甲基-1-萘胺盐酸盐 顺式-4-(3,4-二氯苯基)-1,2,3,4-四氢N-叔丁氧羰基-1-萘胺 顺式-1-苯甲酰氧基-2-二甲基氨基-1,2,3,4-四氢萘 顺式-1,2,3,4-四氢-5-环氧丙氧基-2,3-萘二醇 顺式-(1S,4S)-N-甲基-4-(3,4-二氯苯基)-1,2,3,4-四氢-1-萘胺扁桃酸盐 顺-5,6,7,8-四氢-6,7-二羟基-1-萘酚 顺-(+)-5-甲氧基-1-甲基-2-(二正丙基氨基)萘满马来酸 阿洛米酮 阿戈美拉汀杂质醇(A) 阿戈美拉汀杂质 钠2-羟基-7-甲氧基-1,2,3,4-四氢-2-萘磺酸酯 金钟醇 邻烯丙基苯基溴化镁 那高利特盐酸盐 那高利特 过氧化,1,1-二甲基乙基1,2,3,4-四氢-1-萘基 贝多拉君 螺<4.7>十二烷 蔡醇酮 萘磺酸,二癸基-1,2,3,4-四氢- 萘并[2,3-d]咪唑,2-乙基-5,6,7,8-四氢-(6CI) 萘亚胺 苯甲酸-(5,6,7,8-四氢-[2]萘基酯) 苯甲丁氮酮 苯甲丁氮酮 苯甲丁氮酮 苯并烯氟菌唑 舍曲林二甲基杂质盐酸盐 舍曲林EP杂质B 舍曲林 羟甲基四氢萘酚 美曲唑啉 罗替戈汀硫酸盐 罗替戈汀杂质18 罗替戈汀中间体 罗替戈汀中间体 罗替戈汀 罗替戈汀 纳多洛尔杂质 米贝地尔(二盐酸盐) 盐酸舍曲林 盐酸舍曲林 盐酸罗替戈汀 盐酸左布诺洛尔 盐酸四氢唑林 甲基缩合物 甲基6-[1-(3,5,5,8,8-五甲基-5,6,7,8-四氢-2-萘基)环丙基]烟酸酯 甲基-(2-吡咯烷-1-基甲基-1,2,3,4-四氢-萘-2-基)-胺 环丙烯并[a]茚,1-溴-1-氟-1,1a,6,6a-四氢-